|
1
|
Satow R, Nakamura T, Kato C, Endo M,
Tamura M, Batori R, Tomura S, Murayama Y and Fukami K: ZIC5 drives
melanoma aggressiveness by PDGFD-mediated activation of FAK and
STAT3. Cancer Res. 77:366–377. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Yang J, Price MA, Neudauer CL, Wilson C,
Ferrone S, Xia H, Iida J, Simpson MA and McCarthy JB: Melanoma
chondroitin sulfate proteoglycan enhances FAK and ERK activation by
distinct mechanisms. J Cell Biol. 165:881–891. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Frame MC and Serrels A: FAK to the rescue:
Activated stroma promotes a ‘safe haven’ for BRAF-mutant melanoma
cells by inducing FAK signaling. Cancer Cell. 27:429–431. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kolli-Bouhafs K, Sick E, Noulet F, Gies
JP, De Mey J and Rondé P: FAK competes for Src to promote migration
against invasion in melanoma cells. Cell Death Dis. 5:e13792014.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kurenova E, Ucar D, Liao J, Yemma M,
Gogate P, Bshara W, Sunar U, Seshadri M, Hochwald SN and Cance WG:
A FAK scaffold inhibitor disrupts FAK and VEGFR-3 signaling and
blocks melanoma growth by targeting both tumor and endothelial
cells. Cell Cycle. 13:2542–2553. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Luo X, Peng JM, Su LD, Wang DY and Yu YJ:
Fangchinoline inhibits the proliferation of SPC-A-1 lung cancer
cells by blocking cell cycle progression. Exp Ther Med. 11:613–618.
2016.PubMed/NCBI
|
|
7
|
Li D, Lu Y, Sun P, Feng LX, Liu M, Hu LH,
Wu WY, Jiang BH, Yang M, Qu XB, et al: Inhibition on proteasome β1
subunit might contribute to the anti-cancer effects of
fangchinoline in human prostate cancer cells. PLoS One.
10:e01416812015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sun YF and Wink M: Tetrandrine and
fangchinoline, bisbenzylisoquinoline alkaloids from Stephania
tetrandra can reverse multidrug resistance by inhibiting
P-glycoprotein activity in multidrug resistant human cancer cells.
Phytomedicine. 21:1110–1119. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wang CD, Huang JG, Gao X, Li Y, Zhou SY,
Yan X, Zou A, Chang JL, Wang YS, Yang GX, et al: Fangchinoline
induced G1/S arrest by modulating expression of p27, PCNA, and
cyclin D in human prostate carcinoma cancer PC3 cells and tumor
xenograft. Biosci Biotechnol Biochem. 74:488–493. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wang CD, Yuan CF, Bu YQ, Wu XM, Wan JY,
Zhang L, Hu N, Liu XJ, Zu Y, Liu GL, et al: Fangchinoline inhibits
cell proliferation via Akt/GSK-3beta/cyclin D1 signaling and
induces apoptosis in MDA-MB-231 breast cancer cells. Asian Pac J
Cancer Prev. 15:769–773. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Xing Z, Zhang Y, Zhang X, Yang Y, Ma Y and
Pang D: Fangchinoline induces G1 arrest in breast cancer cells
through cell-cycle regulation. Phytother Res. 27:1790–1794. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Smith CS, Golubovskaya VM, Peck E, Xu LH,
Monia BP, Yang X and Cance WG: Effect of focal adhesion kinase
(FAK) downregulation with FAK antisense oligonucleotides and
5-fluorouracil on the viability of melanoma cell lines. Melanoma
Res. 15:357–362. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sonoda Y, Hada N, Kaneda T, Suzuki T,
Ohshio T, Takeda T and Kasahara T: A synthetic
glycosphingolipid-induced antiproliferative effect in melanoma
cells is associated with suppression of FAK, Akt, and Erk
activation. Biol Pharm Bull. 31:1279–1283. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Thapa B, Koo BH, Kim YH, Kwon HJ and Kim
DS: Plasminogen activator inhibitor-1 regulates infiltration of
macrophages into melanoma via phosphorylation of FAK-Tyr925.
Biochem Biophys Res Commun. 450:1696–1701. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kurenova E, Xu LH, Yang X, Baldwin AS Jr,
Craven RJ, Hanks SK, Liu ZG and Cance WG: Focal adhesion kinase
suppresses apoptosis by binding to the death domain of
receptor-interacting protein. Mol Cell Biol. 24:4361–4371. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Golubovskaya VM, Finch R and Cance WG:
Direct interaction of the N-terminal domain of focal adhesion
kinase with the N-terminal transactivation domain of p53. J Biol
Chem. 280:25008–25021. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sonoda Y, Matsumoto Y, Funakoshi M,
Yamamoto D, Hanks SK and Kasahara T: Anti-apoptotic role of focal
adhesion kinase (FAK). Induction of inhibitor-of-apoptosis proteins
and apoptosis suppression by the overexpression of FAK in a human
leukemic cell line, HL-60. J Biol Chem. 275:16309–16315. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Golubovskaya VM: Targeting FAK in human
cancer: From finding to first clinical trials. Front Biosci
(Landmark Ed). 19:687–706. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Shibue T and Weinberg RA: Integrin
beta1-focal adhesion kinase signaling directs the proliferation of
metastatic cancer cells disseminated in the lungs. Proc Natl Acad
Sci USA. 106:10290–10295. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kaneda T, Sonoda Y, Ando K, Suzuki T,
Sasaki Y, Oshio T, Tago M and Kasahara T: Mutation of Y925F in
focal adhesion kinase (FAK) suppresses melanoma cell proliferation
and metastasis. Cancer Lett. 270:354–361. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Krifa M, El Meshri SE, Bentouati N, Pizzi
A, Sick E, Chekir-Ghedira L and Rondé P: In vitro and in vivo
anti-melanoma effects of pituranthos tortuosus essential oil via
inhibition of FAK and Src activities. J Cell Biochem.
117:1167–1175. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yajima I, Kumasaka MY, Yamanoshita O, Zou
C, Li X, Ohgami N and Kato M: GNG2 inhibits invasion of human
malignant melanoma cells with decreased FAK activity. Am J Cancer
Res. 4:182–188. 2014.PubMed/NCBI
|
|
23
|
Tian F, Ding D and Li D: Fangchinoline
targets PI3K and suppresses PI3K/AKT signaling pathway in SGC7901
cells. Int J Oncol. 46:2355–2363. 2015.PubMed/NCBI
|
|
24
|
Wang N, Pan W, Zhu M, Zhang M, Hao X,
Liang G and Feng Y: Fangchinoline induces autophagic cell death via
p53/sestrin2/AMPK signalling in human hepatocellular carcinoma
cells. Br J Pharmacol. 164:731–742. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Xing ZB, Yao L, Zhang GQ, Zhang XY, Zhang
YX and Pang D: Fangchinoline inhibits breast adenocarcinoma
proliferation by inducing apoptosis. Chem Pharm Bull (Tokyo).
59:1476–1480. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Guo B, Su J, Zhang T, Wang K and Li X:
Fangchinoline as a kinase inhibitor targets FAK and suppresses
FAK-mediated signaling pathway in A549. J Drug Target. 23:266–274.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Guo B, Xie P, Su J, Zhang T, Li X and
Liang G: Fangchinoline suppresses the growth and invasion of human
glioblastoma cells by inhibiting the kinase activity of Akt and
Akt-mediated signaling cascades. Tumour Biol. 37:2709–2719. 2016.
View Article : Google Scholar : PubMed/NCBI
|
